GlassScriptPhysician profile
Robert L Findley
NPI 1881601102
$5,071.06
in general payments reported to CMS, 2019-2025
25 companies · $1,087 in 2025
The $1,087 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,093 · 2022: $1,161 · 2023: $905 · 2024: $824 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,816.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $603.47 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $552.85 | 2021-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $505.50 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $483.27 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $469.67 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $418.87 | 2021-2025 | Caplyta |
| Alkermes, INC. | $243.12 | 2021-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $241.96 | 2021-2025 | Ingrezza |
| Corium, LLC | $180.28 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $169.46 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $159.15 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $147.42 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Bausch Health US, LLC | $114.07 | 2021-2025 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $107.10 | 2022-2024 | Quviviq |
| Lundbeck LLC | $103.08 | 2021-2025 | Rexulti, Abilify Maintena |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $92.93 | 2023-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $83.72 | 2021-2023 | Belsomra |
| Eisai INC. | $73.00 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $63.90 | 2021 | |
| Adlon Therapeutics L.P. | $59.84 | 2021 | |
| Noven Therapeutics, LLC | $59.42 | 2023-2025 | Secuado, Xelstrym |
| Indivior INC. | $45.26 | 2022-2024 | Sublocade |
| Ironshore Pharmaceuticals INC. | $38.68 | 2021-2023 | Jornay Pm |
| Neos Therapeutics, LP | $36.11 | 2024-2025 | Exxua, Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $18.93 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Findley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.